1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Refocused Sophiris to switch to transrectal injection for enlarged prostate drug

 
• By Mandy Jackson

Sophiris Bio will use a transrectal route of administration, rather than the transperineal route, for its lead drug PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate). This follows a three-month 40-patient study which showed that a transrectal ultrasound (TRUS) guided injection directly into the prostate was well tolerated. The selection of the route of administration is another step in a substantial refocusing of the company which saw the appointment of a new CEO, Randall Woods, in mid-August, and a halt to other development projects to allow more resources to be put into the PRX302/BPH program. With its singular focus on the BPH drug, Sophiris hopes to take PRX302 into a Phase III trial later in 2012.

Sophiris Bio will use a transrectal route of administration, rather than the transperineal route, for its lead drug PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate). This follows a three-month 40-patient study which showed that a transrectal ultrasound (TRUS) guided injection directly into the prostate was well tolerated. The selection of the route of administration is another step in a substantial refocusing of the company which saw the appointment of a new CEO, Randall Woods, in mid-August, and a halt to other development projects to allow more resources to be put into the PRX302/BPH program. With its singular focus on the BPH drug, Sophiris hopes to take PRX302 into a Phase III trial later in 2012.

The switch in drug administration route for PRX302 is for physician convenience, according to Sophiris. "The decision to move to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By Manas Mishra

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

More from Therapeutic Category

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.